Strategie investment in preventive health care: Quantitative modelling for programme selection and resource allocation

OR Spectrum

Volumn 18, Issue 1, 1996, Pages 1-14

  Heidenberger, Kurt ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cost effectiveness analysis; Economics of health technology; Health investment; Prevention; Programme selection; Resource allocation

Indexed keywords

EID: 0038194859     PISSN: 01716468     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01539875     Document Type: Article

References (149)

1. Ahmed R (1978) On optimal resource allocation in community hypertension programs. Mgmt Sci 24:1749-1752
2. Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941-973
3. A Who Meeting (1986) The use of quantitative methods in planning national cancer control programmes. Bull Wrld Hlth Org 64(5): 683-693
4. Bailey NTJ (1975) The mathematical theory of infectious diseases and its application. Hafner-Press, New York
5. Baker S. Heidenberger K (1989) Choosing sample sizes to maximize health benefits subject to a constraint on total trial costs. Med Dec Making 9:14-25
6. Barlow R (1967) The economic effects of malaria eradication. Am Econ Rev 57 (App): 130-148
7. Bierman H, Smidt S (1993) The capital budgeting decision: economic analysis of investment projects. 8th edn. Macmillan, New York
8. Blum H (1981) Planning for health: generics for the eighties. 2nd edn. Human Sciences Press, New York
9. Boyd A, Davies LA, Bagust A (1989) Modelling the implications for hospital services of cervical cytology screening: a case history. J Opl Res Soc 40:529-537
10. Brandeau ML, Lee HL, Owens DK, Sox CH, Wachter RM (1991) A policy model of human immunodeficiency virus screening and intervention. Interfaces 21(3):5-25
11. Brandeau ML, Owens DK, Sox CH, Wachter RM (1993) Screening women of childbearing age for human immunodeficiency virus: a model-based policy analysis. Mgmt Sci 39:72-92
12. Brooks RG (1986) The development and construction of health status measures. IHE report 1986:4. The Swedish Institute for Health Economics, Lund
13. Brooks RG (1988) Scaling in health status measurement: an outline guide and commentary. IHE report 1988: 4. The Swedish Institute for Health Economics, Lund
14. Bross IDJ, Blumenson LE (1968) Statistical testing of a deep mathematical model for human breast cancer. J Chron Dis 21:493-506
15. Chorba RW, Sanders JL (1971) Planning models for tuberculosis control. Hlth Serv Res 6(2): 144-164
16. Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
17. Creese A (1983) The economic evaluation of immunization programmes. In: Lee K, Mills A (eds.) The economics of health in developing countries. Oxford University Press, Oxford
18. Cretin S ( 1977) Cost-benefit analysis of treatment and prevention of myocardial infarction. Hlth Serv Res 12(2):174-189
19. Crystal R, Brewster A (1966) Cost-benefit and cost-effectiveness analysis in the health field: an introduction. Inquiry 3:3-13
20. Culyer AJ (ed.) (1983) Health indicators. Martin Robertson, London
21. Detsky AS (1985) Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chron Dis 38:753-765
22. Dorfman R (ed) (1965) Measuring benefits of government investments. The Brookings Institution, Washington, D.C.
23. Drummond MF (1980) Principles of economic appraisal in health care. Oxford University Press, Oxford
24. Drummond MF (1989) Output measurement for resource allocation decisions in health care. Oxford Rev Econ Policy 5(1):59-74
25. Drummond MF, Stoddart GL, Torrance GW (1987) Methods of the economic evaluation of health care programmes. Oxford University Press, Oxford
26. Drummond MF, Heyse J, Cook J, McGuire A (1993) Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Dec Making 13:184-190
27. Dunlop D (1975) Benefit-cost analysis: a review of its applicability in policy analysis for delivering health services. Soc Sci Med 9:133-139
28. Eddy DM (1980) Screening for cancer: theory, analysis and design. Prentice Hall, Englewood Cliffs, NJ
29. Eddy DM (1986) A computer-based model for designing cancer control strategies. Nat Cane Inst Monogr 2:75-82
30. Eddy DM, Shwartz M (1982) Mathematical models in screening. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Saunders, Philadelphia, PA
31. Farrington CP (1989) Optimal screening policies for Hepatitis A. J Opl Res Soc 40:355-359
32. Feldstein MS, Piot MA, Sundaresan TK (1973) Resource allocation model for public health planning: a case study of tuberculosis control. Bull Wrld Hlth Organ 48 (Suppl.):1-110
33. Fineberg H (1983) Impact of technological investment on the cost of the health care system. J Neuroradiol 10:199-204
34. Fineberg HV, Hiat HH (1979) Evaluation of medical practices: the case of technology assessment, N Engl J Med 301:1086-1091
35. Fuchs V (1979) The economics of health in a post-industrial society. The Public Interest (Summer):3-20
36. Fuchs V (1980) What is CBA/CEA, and why are they doing this to us. N Engl J Med 303:937-938
37. Fuchs V (1986) The health economy. Harvard University Press, Cambridge, MA
38. Gail MH, Preston D, Piantadosi S (1989) Disease prevention models of voluntary confidential screening for human immunodeficiency virus (HIV). Stat Med 8:59-81
39. Ganiats TG (1994) Discounting in cost-effectiveness research. Med Dec Making 14:298-300
40. Gelijns AC, Halm EA (eds) (1991) Medical innovation at the crossroads, Vol 2: The changing economics of medical technology. National Academy Press, Washington D.C.
41. Goldman TA (ed) (1967) Cost-effectiveness analysis: new approaches in decision making. Washington Operations Research Council (Frederic A. Praeger), New York
42. Habbema JDF, Lubbe JTN, Oortmarssen GJ van, Maas PJ van der (1987) A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J Opl Res 29:159-166
43. Hall NJ, Hershey JC, Kessler L, Stotts RC (1992) A model for making project funding decisions at the National Cancer Institute, Ops Res 40:1040-1052
44. Hartunian NS, Smart CN, Thompson MS (1980) The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Publ Hlth 70:1249-1260
45. Heidenberger K (1982 a) Gruppenspezifische Auswahl von Diagnosestrategien im Bereich der Hypertoniefrüherkennung. Ein Modell der linearen 0/1-Programmierung. OR Spektrum 4:91-104
46. Heidenberger K (1982b) Hypertension policy analysis allowing for group-specific diagnostic strategies. Methods Inf Med 21: 197-204
47. Heidenberger K (1983) Strategische Analyse der sekundären Hypertonieprävention. Springer, Berlin
48. Heidenberger K (1988a) Strategische Planung horizontal und vertikal differenzierter Gesundheitsprogramme. OR Spektrum 4: 221-235
49. Heidenberger K (1988b) Optimal resource allocation in horizontally and vertically disaggregated health programs. In: Fandel G (ed) Management problems in health care. Springer, Berlin
50. Heidenberger K (1990 a) Dynamische Gesundheitsprogrammplanung: Ein strategisches Modell der Nichtlinearen Programmierung. OR Spektrum 12:163-172
51. Heidenberger K (1990b) Quantitative Modelle für das Strategische Management. Springer, Berlin
52. Heidenberger K (1992) Strategic decision support in preventive health care. Soc-Econ Plann Sci 26:129-146
53. Heidenberger K (1994) Health related product innovation in life insurance: a micro-simulation based decision support system. Paper presented at the 13th European and 36th National Congress on Operational Research, Glasgow, July 19-22
54. Heidenberger K, Flessa S (1991) AIDS-Dynamik in Tansania: eine strategische Simulation. Off Gesundh Wes 53:241-249
55. Heidenberger K, Flessa S (1993) A system dynamics model for AIDS policy support in Tanzania. Eur J Opl Res 70:167-176
56. Hethcote HW, Yorke JA (1984) Gonorrhea transition dynamics and control. Springer, New York
57. Homer JB, St. Clair CLS (1991) A model of HIV transmission through needle sharing. Interfaces 21(3):26-49
58. Houshyar A, Al-Khayyal (1990) A mathematical model for scheduling screening tests for progressive diseases. Soc-Econ Plann Sei 24:187-197
59. Iglehart JK (1982) Health care and American business. N Engl J Med 306:120-124
60. Kamlet MS (1992) The comparative benefits modeling project: a framework for cost-utility analysis of government health care programs. U.S. Government Printing Office, Washington D.C.
61. Kannel W, McGee D, Gordon T (1976) A general cardiovascular risk profile: The Frarningham study. Am J Cardiol 38:46-51
62. Kaplan EH (1989) What are the risks of risky sex? Modeling the AIDS epidemic. Ops Res 37:198-209
63. Kaplan EH, Brandeau ML (1994) Modeling the AIDS epidemic: planning, policy, and prediction. Raven Press, New York
64. Keeler EB, Cretin S (1983) Discounting of life-saving and other nonmonetary outcomes. Mgmt Sci 29:300-306
65. Kermack WO, McKendrick AG (1927, 1932, 1933) Contributions to the mathematical theory of epidemics. Proc R Soc 115: 700-721;
66. Kermack WO, McKendrick AG (1927, 1932, 1933) Contributions to the mathematical theory of epidemics. Proc R Soc 138:55-83;
67. Kermack WO, McKendrick AG (1927, 1932, 1933) Contributions to the mathematical theory of epidemics. Proc R Soc 141:94-122
68. Kessler L, Taylor P (1989) Prevention trials (Editorial). Med Dec Making 9:1-2
69. Klarman HE (1965) Syphilis control programs. In: Dorfman R (ed.) Measuring benefits of government investments. The Brooking Institution, Washington, D.C.
70. Klarman HE (1974) Application of cost-benefit analysis to the health services and the special case of technological innovation. Int J Hlth Serv 4:325-352
71. Klarman HE (1982) The road to cost-effectiveness analysis. Milbank Meml Fund Q 60:585-603
72. Knox EG (1973) A simulation system for screening procedures. Problems and progress in medical care 9:19-55
73. Kristein MM (1977) Economic issues in prevention. Prev Med 6:252-264
74. Kristein MM (1980) The economics of screening for colo-rectal cancer. Soc Sci Med 14C:275-284
75. Kristein MM (1983) Using cost-effectiveness and cost-benefit analysis for health care policy making. Adv Hlth Econ Hlth Serv Res 4:199-224
76. Kristein MM, Arnold CB, Wynder EL (1977) Health economics and preventive care. Science 195:457-462
77. Lairson DR, Swint JM (1988) Economic considerations in technology assessment: the case of genetic disease. Hlth Policy 9: 309-315
78. Lee HL, Pierskalla WP (1988) Mass screening models for contagious diseases with no latent period. Ops Res 36:917-928
79. Lipscomb J (1989) Time preferences for health in cost-effectiveness analysis. Med Care 27:233-253
80. Manton KG (1985) Procedures for evaluating the population-level impact of primary prevention: a review of models for risk assessment forecasting on impact determination. A report prepared for the World Health Organization. Division of Noncommunicable Diseases. Center for Demographic Studies, Duke University, Durham, NC
81. Margolis J (1977) Shawdow prices for incorrect or nonexistent market values. In: Haveman RH, Margolis J (eds.) Public expenditure and policy analysis, 2nd edn. Rand McNally, Chicago
82. McKinlay JB, McKinlay SM (1977) The questionable contribution of medical measures to the decline of mortality in the United States in the twentieth century. Milbank Meml Fund Q 55: 405-428
83. McNeil BJ, Dudley RA, Hoop B, Metz C, Thompson M, Adelstein SJ (1981) A cost-effectiveness analysis of screening for hepatitis B surface antigen in India. Med Dec Making 1:345-359
84. Milsum JH (1989) Determining optimal screening policies, using decision trees and spreadsheets. Comp Biol Med 19:231-243
85. Milsum JH (1991) On the optimization of cholesterol screening. Methods Inf Med 30:36-43
86. Moses S, Plummer FA, Ngugi EN, Nagelkerke NJD, Anzada AO, Ndinya-Acjola JO (1991) Controlling HIV in Africa: effectiveness and cost of an intervention in high-frequency STD transmitter groups. AIDS 5:407-411
87. Moskowitz H, Plante R, Tsai HT (1993) A multistage screening model for evaluation and control of misclassification error in the detection of hypertension. Mgmt Sci 39:307-321
88. Mosteller F, Weinstein MC (1985) Toward evaluating the cost-effectiveness of medical and social experiments. In: Hausman JA, Wise DA (eds.) Social experimentation. University of Chicago Press, Chicago
89. Mushkin S (1958) Toward a definition of health economics. Publ Hlth Rep 73:785-793
90. Mushkin SJ (1962) Health as an investment. J Polit Econ 70 (Oct. Suppl.): 129-157
91. Neuhauser D, Stason WB ( 1980) Cost-effective clinical decision making. In: Carels EJ, Neuhauser D, Stason WB (eds.) The physician and cost control. Oelgeschlager, Gunn & Hain, Cambridge, MA
92. Nichols AL, Weinstein MC (1978) Optimal resource allocation in community hypertension programs. Mgmt Sci 24:1526-1537
93. O'Brien B, Viramontes JL (1994) Willingness to pay: a valid and reliable measure of health state preference? Med Dec Making 14: 289-297
94. Office of Technology Assessment, U.S. Congress (1980) The implications of cost-effectiveness analysis of medical technology. Background paper no. 1:Methodological issues and literature review. U.S. Government Printing Office, Washington, D.C.
95. Oortmarssen GJ van, Habbema JDF, Lubbe JTN, Jong GA de, Maas PJ van der (1981) Predicting the effects of mass screening for disease - a simulation approach. Eur J Opl Res 6:399-409
96. Özekici S, Pliska SR (1991) Optimal scheduling of inspections: a delayed Markov model with false positives and negatives. Ops Res 39:261-273
97. Packer AH (1968) Applying cost-effectiveness concepts to the community health system. Ops Res 16:227-253
98. Parker BR (1978) Quantitative decision techniques for the health/ public sector: an analysis and classification of resources. J Hlth Politics Policy Law 3:388-429
99. Parker BR (1983) A program selection/resource allocation model for control of malaria and related parasitic diseases. Comput Ops Res 10:375-389
100. Parker BR (1990) In quest of useful health care decision models for developing countries. Eur J Opl Res 49:279-288
101. Petersen CC (1981 a) Cost of cardiovascular disease and planning for future directions of the U.S. Air Force HEART program. Prev Med 10:277-286
102. Petersen CC (1981b) Manpower modeling in cost-effectiveness studies of USAF program to reduce the incidence of heart disease. Nav Res Logist Q 28:157-168
103. Petersen CC (1982) Simulation of alternative designs of a cardiovascular risk reduction program for the U.S. Air Force. J Med Sys 6(2): 149-164
104. Prest AR, Turvey R (1965) Cost-benefit analysis: a survey. Econ J 75:683-735
105. Prorok PV (1984) Evaluation of screening programs for the early detection of cancer. In: Cornell RG (ed) statistical methods for cancer studies. Marcel Dekker, New York
106. Ravindran A, Sadagopan A, Petersen CC, Hatsell CP (1980) Using simulation in cardiovascular disease control. Simulation (July): 13-20
107. Redelmeier DA, Heller DN (1993) Time preference in medical decision making and cost-effectiveness analysis. Med Dec Making 13:212-217
108. Redelmeier DA, Heller DN, Weinstein MC (1994) Time preference in medical economics: science or religion? Med Dec Making 14:301-303
109. Reilly CH, Petersen CC (1988) Implementation planning for a USAF-wide cardiovascular-risk-reduction program. IIE Transact 20:97-102
110. Reisman A, Kirschnick F (1994) The devolution of OR/MS: implications from a statistical content analysis of three flagship journals. Ops Res 42:577-588
111. ReVelle C, Lynn WR, Feldman F (1967) Mathematical models for the economic allocation of tuberculosis control activities in developing nations. Am Rev Resp Dis 96:893-909
112. ReVelle C, Feldman F, Lynn W (1969) An optimization model of tuberculosis epidemiology. Mgmt Sci 16:B190-B211
113. Rice DP, Hodgson TA, Kopstein AN (1985) The economic cost of illness: a replication and update. Hlth Care Finan Rev 7:61-80
114. Rogers PJ, Eaton EK, Bruhm JG (1981) Is health promotion cost-effective? Prev Med 10:324-339
115. Rowley JT, Anderson RM (1994) Modelling the impact and cost-effectiveness of HIV prevention efforts. AIDS 8:539-548
116. Russell LB (1984) The economics of prevention. Hlth Policy 4: 85-100
117. Russell LB (1986) Is prevention better than cure. The Brookings Institution, Washington, D.C.
118. Russell LB (1987) The economics of prevention: reply to Roy Shepard. Hlth Policy 7:57-59
119. Rutten FFH, Drummond MF (1994) Making decisions about health technologies: a cost-effectiveness perspective. Institute for Medical Technology Assessment, University of York, York, UK
120. Schieber GJ, Poullier JP, Greenwald LM (1993) Health spending, delivery and outcomes in OECD countries. Hlth Affairs 12(2): 120-129
121. Schwartz JS, Kinosian B, Pierskalla WP, Lee HL (1990) Strategies for screening blood for human immunodeficiency virus antibody. J Am Med Assoc 264:1704-1710
122. Shepard DS, Thompson MS (1979) First principles of cost-effectiveness analysis in health. Publ Hlth Rep 94:535-543
123. Shepard DS, Zeckhauser RJ (1984) Survival versus consumption. Mgmt Sci 30:423-439
124. Shepard RJ (1987) The economics of prevention: a critique. Hlth Policy 7:49-56
125. Shwartz M (1978) A mathematical model used to analyse breast cancer screening strategies. Ops Res 26:937-955
126. Shwartz M (1992) Validation of a model of breast cancer screening: an outlier observation suggests the value of breast self examination. Med Dec Making 12:222-228
127. Shwartz M, Plough Al (1984) Models to aid in planning cancer screening programs. In: Cornell RG (ed) Statistical methods for cancer studies. Marcel Dekker, New York
128. Smith WF (1968) Cost-effectiveness and cost-benefit analysis for public health programs. Publ Hlth Rep 83:899-906
129. Sondik EJ, Stahr W, Haines CM, Jones HH, Renich P (1979) Interactive hypertension treatment model for the National High Blood Pressure Education Program. Paper presented at the National Conference on High Blood Pressure. Washington, D.C., April (typescript)
130. Thompson MS (1983) Health versus money: value judgements in the perspective of decision analysis. Med Dec Making 3:285-297
131. Thompson MS, Fortess EE (1980) Cost-effectiveness analysis in health program evaluation. Eval Rev 4:549-568
132. Tormans G, Damme P van, Carrin G, Clara R, Eylenbosch W (1993) Cost-effectiveness analysis of prenatal screening and vaccination against Hepatitis B virus - the case of Belgium. Soc Sci Med 37:173-181
133. Torrance GW (1986) Measurement of health state utilities for economic appraisal: a review. J Hlth Econ 4:1-130
134. Treasury HM (1982) Investment appraisal in the public sector. Her Majesty's Stationary Office, London
135. Tsevat J (1992) Impact and cost-effectiveness of smoking interventions. Am J Med 93(1 A):43S-47S
136. Tsodikov AD, Yakovlev AY (1991) On the optimal policies of cancer screening. Math Biosci 107:21-45
137. Urban N, Baker M (1989) The women's health trial as an investment. Med Dec Making 9:59-64
138. Voelker JA, Pierskalla WP (1980) Test selection for a mass screening program. Nav Res Logist Q 27:43-56
139. Wagner G, Tautu D, Wolber U (1981) Screening for cancer: publications 1971-1980. Methods Inf Med 20:223-251
140. Walker A, Whynes DK (1992) Filtering strategies in mass population screening for colorectal cancer: an economic evaluation. Med Dec Making 12:2-7
141. Warner KE (1979) The economic implications of preventive health care. Soc Sci Med 13C:227-237
142. Warner KE, Luce BR (1982) Cost-benefit and cost-effectiveness analysis in health care: principles, practice and potential. Health Administration Press, Ann Arbor, MI.
143. Weinstein MC (1981) Economic assessment of medical practices and technologies. Med Dec Making 1:309-330
144. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721
145. Weinstein MC, Coxson PG, Williams LW, Pas TM, Stason WB, Goldman L (1987) Forecasting coronary heart disease incidence, mortality and cost: the coronary heart disease policy model. Am J Publ Hlth 77:1417-1426
146. Weisbrod BA (1971) Costs and benefits of medical research: a case study of poliomyelitis. J Polit Econ 79:527-544
147. Weisbrod BA, Huston JHC (1983) Benefits and costs of human vaccines in developed countries: an evaluative survey. Center for Health Economics and Law, Department of Economics, University of Wisconsin-Madison, Discussion Paper # 210
148. Woodbury MA, Manton KG, Stallard E (1981) Longitudinal models for chronic disease risk: an evaluation of logistic multiple regression and alternatives. Int J Epidem 10(2):187-197
149. Yu SZ, Miller AB, Sherman GJ (1982) Optimizing the age, number of tests and test interval for cervical cancer screening in Canada: J Epid Comm Hlth 3:1-10